US 12502357

As a senior US patent analyst, I have reviewed the provided information for US patent 12502357. Below is a concise summary based on the authoritative patent text.

Summary of US Patent 12502357

Title: Formulations of enzalutamide

Assignee at Issue:

• Astellas Pharma Inc
• Medivation Prostate Therapeutics LLC

Inventors:

• Douglas Alan Lorenz
• Sanjay Konagurthu
• Randy J. Wald
• Jason A. Everett
• Sheila Matz
• Yuuki Takaishi
• Toshiro Sakai
• Ryousuke Irie
• Shinsuke Oba
• Hiroyasu Toyota
• Koji Nishimura
• Atsushi Kanbayashi

Filing Date: December 4, 2024

Issue Date: December 23, 2025

Abstract:
The patent text does not contain a formal abstract. However, the "Definitions" section begins with the statement: "This disclosure relates to solid formulations of enzalutamide." This indicates the patent's focus is on creating stable, solid forms of the drug enzalutamide, which is used in cancer therapy.

Plain-Language Overview of Independent Claims:
I do not have access to the specific numbered claims for US Patent 12502357. The provided text, while extensive, lacks the formal "Claims" section that defines the legal scope of the invention. An analysis of the independent claims cannot be performed without this section.

Litigation Status

A search of the CAFC (Court of Appeals for the Federal Circuit) 2026 dockets for patent number 12502357 did not yield any results. This suggests that, as of today's date, there is no active litigation involving this patent at the appellate level.

Uncertainty Note: The summary of the title, assignees, inventors, and key dates is provided with high confidence based on the supplied patent text. However, the absence of the formal "Abstract" and "Claims" sections in the provided document means that a complete analysis of the patent's scope and a summary of its specific legal protections cannot be authoritatively completed.